✨ Free AI Report
GenSight Biologics: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research GenSight Biologics
Company Research

GenSight Biologics: Business Overview, Financials & Competitive Analysis

GenSight Biologics scores 4/10 on the AskCyborg Cyborg Score (Mixed). Early-stage gene therapy company at critical inflection point with lead asset progressing through regulatory pathways but facing liquidity and development challenges. 2024 was a year of strategic transformation including challenges such as management transition, implementation of an additional blending step in LUMEVOQ manufacturing, and extended timelines for the French paid.

What is GenSight Biologics's industry? GenSight Biologics (gensight-biologics.com) operates in Biotechnology / Gene Therapy / Ophthalmology. AskCyborg classifies GenSight Biologics under Biotechnology / Gene Therapy / Ophthalmology in its company registry.

GenSight Biologics is a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. Founded in 2012, the company r...

4/ 10Mixed

Cyborg Score thesis

Early-stage gene therapy company at critical inflection point with lead asset progressing through regulatory pathways but facing...

Read the full analyst-debate transcript →
Industry Biotechnology / Gene Therapy / Ophthalmology
2 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest GenSight Biologics Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for GenSight Biologics

AskCyborg analysts argue the bull and bear cases for GenSight Biologics across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
GenSight Biologics OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

GenSight Biologics Overview

Pro stress-test →

GenSight Biologics is a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. Founded in 2012, the company represents a pioneering effort to address severe vision loss conditions with limited treatment options through proprietary gene therapy platforms.

Strategic Profile

Pro stress-test →

The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. The company has a portfolio of 2 products, including 1 in phase III clinical development (Lumevoq for the treatment of Leber's hereditary optic neuropathy) and 1 in phase I/II clinical development (GS030 for the treatment of retinitis pigmentosa). The company is preparing for the launch in H2 2026 of the pivotal Phase III study RECOVER for GS010/LUMEVOQ.

Competitive Landscape

Pro stress-test →

GenSight is pursuing opportunities to out-license GS010 in markets outside the USA and Europe, while exploring paid Early Access Programs worldwide. The company operates in the specialized gene therapy space for inherited retinal diseases where direct competitors include Luxturna (Novartis) and emerging developers. GenSight's differentiated MTS platform targeting mitochondrial dysfunction offers potential competitive positioning.

Industry Context

GenSight Biologics operates in Biotechnology / Gene Therapy / Ophthalmology.

Key facts

Founded: 2012 · Headquarters: Paris, France

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on GenSight Biologics.

  • GenSight progressed in its early access program with individual patient authorizations in France and Israel and an individual IND approval in the United States
  • The company is completing technology transfer to its new manufacturing partner, Catalent, expected to be finalized by year-end 2025, with new batch production in 2026 to address full scope of projected clinical and early access needs
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Strategic expansion of regulatory team with senior appointments ahead of pivotal trials
  • October 2025FDA authorization for expanded access treatment of individual patient in the United States
  • +1 moreTrack every material event for GenSight Biologics as it happens. Explore monitoring →
Get alerted when GenSight Biologics has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

LuxturnaGene therapy for retinitis pigmentosa from RPE65 mutations→Emerging gene therapiesOther optogenetics and retinal gene therapy platforms in development→

Compare GenSight Biologics with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

GenSight Biologics operates in Biotechnology / Gene Therapy / Ophthalmology. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biotechnology by Cyborg Score

Browse Biotechnology / Gene Therapy / Ophthalmology research →
NEW · MCP server

Ask your AI assistant about GenSight Biologics

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare GenSight Biologics and its top competitor on Cyborg Score”
“What did GenSight Biologics do this quarter?”
“Is GenSight Biologics a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does GenSight Biologics do?+
GenSight Biologics is a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. Founded in 2012, the company r...
What is GenSight Biologics's Cyborg Score?+
GenSight Biologics has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are GenSight Biologics's main competitors?+
Named competitors include Luxturna, Emerging gene therapies. The full competitive landscape is in the AskCyborg report.
How can I get the full GenSight Biologics research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the GenSight Biologics research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track GenSight Biologics over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biotechnology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Abivax SA8Bavarian Nordic A/S8Beam Therapeutics Inc.8CG Oncology, Inc.8Cogent Biosciences, Inc.8COMPASS Pathways plc8CSL Limited8Eckert & Ziegler SE8Krystal Biotech, Inc.8Legend BiotechTop companies in Biotechnology by Cyborg Score